Physician profile
Gregory Jansyn
NPI 1639250632
$1,331.04
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $181 · 2021: $18.36 · 2022: $461 · 2023: $26.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $270.17 | 2019-2023 | Physio-Stim |
| Zyla Life Sciences, INC. | $129.13 | 2019-2020 | |
| Royal Biologics, INC. | $119.39 | 2019 | |
| Osiris Therapeutics INC. | $119.37 | 2019 | |
| Horizon Therapeutics Plc | $111.36 | 2020-2022 | |
| Angiodynamics, INC. | $107.22 | 2022 | |
| Tactile Systems Technology INC | $106.42 | 2019 | |
| Paratek Pharmaceuticals, INC. | $98.36 | 2022 | |
| Medline Industries LP | $94.14 | 2019 | |
| Collaborative Care Diagnostics, LLC | $47.99 | 2022 | |
| Smith+Nephew, INC. | $46.85 | 2021-2022 | |
| Abbott Laboratories | $46.01 | 2022 | |
| Organogenesis INC. | $12.73 | 2023 | Puraply |
| Alfasigma USA, INC. | $11.18 | 2020 | |
| Fidia Pharma USA INC. | $10.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Jansyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.